特宝生物
(688278)
| 流通市值：329.02亿 | | | 总市值：329.02亿 |
| 流通股本：4.07亿 | | | 总股本：4.07亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 333,254,167.74 | 284,902,844.18 | 655,378,671.04 | 412,956,945.26 |
| 应收票据及应收账款 | 577,913,926.23 | 531,699,741.61 | 397,987,170.72 | 441,022,155.69 |
| 其中：应收票据 | 27,059,360.06 | 70,727,047.56 | 3,230,355 | 3,211,662 |
| 应收账款 | 550,854,566.17 | 460,972,694.05 | 394,756,815.72 | 437,810,493.69 |
| 预付款项 | 56,880,697.92 | 64,068,072.5 | 34,378,893.94 | 23,389,114.21 |
| 其他应收款合计 | 35,872,420.44 | 31,666,805.88 | 31,779,925.95 | 17,800,218.99 |
| 存货 | 252,749,398.6 | 230,111,701.01 | 216,096,029.95 | 187,017,724.74 |
| 其他流动资产 | 1,587,135.49 | 1,339,258.28 | 976,514.44 | 923,793.45 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,509,551,461.82 | 1,283,654,006.94 | 1,336,597,206.04 | 1,340,191,036.92 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 58,035,623.14 | 58,035,033.22 | 52,863,797.4 | 37,350,684.93 |
| 固定资产 | 322,369,811.89 | 316,095,888.4 | 302,552,453.62 | 298,750,566.63 |
| 在建工程 | 304,445,296.16 | 259,971,991.27 | 244,991,859.76 | 183,715,136.39 |
| 使用权资产 | 9,716,112.2 | 10,562,593.76 | 8,145,334.45 | 8,387,072.11 |
| 无形资产 | 179,073,372.45 | 173,827,252.77 | 182,635,422.8 | 191,539,966.96 |
| 开发支出 | 192,881,019.38 | 183,176,125.19 | 173,157,902.03 | 161,110,873.96 |
| 长期待摊费用 | 17,757,977.77 | 19,368,739.09 | 16,393,114.21 | 15,590,758.66 |
| 递延所得税资产 | 42,975,772.92 | 43,883,892.8 | 40,530,714.57 | 43,662,001.45 |
| 其他非流动资产 | 46,509,166.73 | 56,172,559.48 | 69,045,472.81 | 75,788,996.16 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,173,764,152.64 | 1,121,094,075.98 | 1,090,316,071.65 | 1,015,896,057.25 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,683,315,614.46 | 2,404,748,082.92 | 2,426,913,277.69 | 2,356,087,094.17 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 56,355,580.81 | 30,648,852.06 | 43,811,900.36 | 40,624,624.97 |
| 应付账款 | 56,355,580.81 | 30,648,852.06 | 43,811,900.36 | 40,624,624.97 |
| 合同负债 | 62,140,015.12 | 68,742,405.51 | 67,565,171.32 | 60,053,059.95 |
| 应付职工薪酬 | 131,297,684.32 | 133,586,827.3 | 131,788,428.5 | 197,168,787.69 |
| 应交税费 | 56,117,089.22 | 42,478,832.82 | 52,413,128.59 | 65,090,483.07 |
| 其他应付款合计 | 38,813,361.46 | 34,985,075.42 | 47,367,575.23 | 36,414,615.48 |
| 一年内到期的非流动负债 | 4,452,043.69 | 4,329,054.73 | 4,524,695.7 | 4,163,351.22 |
| 其他流动负债 | 126,732.08 | 247,509.56 | 154,236.75 | 142,691.83 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 349,302,506.7 | 315,018,557.4 | 347,625,136.45 | 403,657,614.21 |
| 非流动负债: | | | | |
| 租赁负债 | 5,450,600.99 | 5,871,596.77 | 3,000,516.58 | 3,760,668.04 |
| 预计负债 | 28,633,447.41 | 31,781,265.02 | 31,418,928.71 | 31,246,034.77 |
| 递延收益 | 34,467,452.68 | 37,571,519.19 | 39,082,851.7 | 40,616,377.04 |
| 递延所得税负债 | 913,646.15 | 549,933.39 | 576,910.2 | 405,057.39 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 69,465,147.23 | 75,774,314.37 | 74,079,207.19 | 76,028,137.24 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 418,767,653.93 | 390,792,871.77 | 421,704,343.64 | 479,685,751.45 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 406,800,000 | 406,800,000 | 406,800,000 | 406,800,000 |
| 资本公积 | 397,824,362 | 397,038,962 | 397,038,962 | 397,038,962 |
| 盈余公积 | 117,548,442.81 | 117,548,442.81 | 117,548,442.81 | 117,548,442.81 |
| 未分配利润 | 1,342,375,155.72 | 1,092,567,806.34 | 1,083,821,529.24 | 955,013,937.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,264,547,960.53 | 2,013,955,211.15 | 2,005,208,934.05 | 1,876,401,342.72 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,264,547,960.53 | 2,013,955,211.15 | 2,005,208,934.05 | 1,876,401,342.72 |
| 负债和股东权益合计 | 2,683,315,614.46 | 2,404,748,082.92 | 2,426,913,277.69 | 2,356,087,094.17 |
| 公告日期 | 2024-10-25 | 2024-08-22 | 2024-04-23 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |